Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action inhibitors, stimulants |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Preclinical | Guatemala | 26 Oct 2024 | |
Melanoma | Preclinical | Guatemala | 26 Oct 2024 | |
Non-Small Cell Lung Cancer | Preclinical | Guatemala | 26 Oct 2024 | |
Pancreatic Cancer | Preclinical | Guatemala | 26 Oct 2024 | |
Prostatic Cancer | Preclinical | Guatemala | 26 Oct 2024 | |
Sarcoma | Preclinical | Guatemala | 26 Oct 2024 | |
Small Cell Lung Cancer | Preclinical | Guatemala | 26 Oct 2024 |